Clinical trials: Neoplasms, Ovarian
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05256381
- Testing
- Nanrilkefusp Alfa, Pembrolizumab
- Where
- 54 sites in United States, Belgium and 7 more
- Volunteers
- 166 people
- Sponsor
- SOTIO Biotech AG
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Peritoneal Carcinomatosis, Ovarian Cancer
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade…
- Trial name
- NCT06504147
- Testing
- Radspherin
- Where
- 10 sites in United States, Belgium and 4 more
- Volunteers
- 114 people
- Sponsor
- Oncoinvent Solutions AS
Ovarian Cancer
Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer
RATIONALE: Diagnostic procedures using the drug radiolabeled folic acid and imaging may be effective in detecting ovarian cancer.
- Trial name
- NCT00003763
- Testing
- radionuclide imaging, indium In 111 folic acid
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Endocyte
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors, Selected Solid Tumors
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of the orally administered phosphatidylinositol 3'-kinase (PI3K) inhibitor…
- Trial name
- NCT01363232
- Testing
- BKM120 + MEK162
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 89 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Advanced Solid Tumours, Breast Cancer
A Study of IMP4297 in Patients With Advanced Solid Tumors
This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT03508011
- Testing
- IMP4297
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Impact Therapeutics, Inc.
Cancer
Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned
The purpose of this study is to determine the recommended dose of I-131-CLR1404, a radiolabeled therapy compound, for treating subjects with cancer that does not respond to treatment or has returned.
- Trial name
- NCT01495663
- Testing
- I-131-CLR1404
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Cellectar Biosciences, Inc.
Polycystic Ovary Syndrome
Inositol Treatment in Different Type of PCOS Phenotype
Evaluation of the efficacy of inositol treatment in women with PCOS in relation to the phenotype (according to the Rotterdam Criteria)
- Trial name
- NCT05678114
- Testing
- Myo-inositol
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Lo.Li.Pharma s.r.l
Breast Cancer, Small Cell Lung Cancer
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity…
- Conditions
- Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT06257264
- Testing
- BG-68501, Fulvestrant, BGB-43395
- Where
- 24 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- BeiGene
Ovarian Cancer
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
This prospective non-interventional study is intended to generate new data and insights into first-line (1L) treatment of newly diagnosed advanced high-grade epithelial Ovarian cancer (OC) in Germany relevant for patients…
- Trial name
- SCOUT-1 (NCT04830709)
- Where
- 89 sites in Germany
- Volunteers
- 752 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT06549816
- Testing
- sigvotatug vedotin
- Where
- 3 sites in China
- Volunteers
- 6 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics…
- Conditions
- Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma
- Trial name
- NCT05293496
- Testing
- vobramitamab duocarmazine, lorigerlimab
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- MacroGenics
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07545460
- Testing
- BL-M07D1, Liposomal Doxorubicin, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 404 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neoplasms, Colorectal Neoplasms
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
- Conditions
- Neoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms
- Trial name
- ALpha-T (NCT04644315)
- Testing
- Alectinib
- Where
- 29 sites in United States
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.
Ovarian, Primary Peritoneal
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This is a multiregional, multicenter, randomized, open-label, phase III study to compare the efficacy, safety, and tolerability of IBI354 monotherapy with investigator's choice of chemotherapy (paclitaxel, gemcitabine, liposomal…
- Conditions
- Ovarian, Primary Peritoneal, Fallopian Tube Cancer
- Trial name
- NCT06834672
- Testing
- IBI354, paclitaxel/Gemcitabine/Liposomal doxorubicin
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ovarian Neoplasms
Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- EMBER (NCT02781272)
- Testing
- Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Angle plc
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.